AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04883736
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Trial: NCT04978025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
Trial: NCT01752270
Drug: Diane-35 pretreatment
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
Trial: NCT01752270
Drug: Diane-35 pretreatment
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04520412
Drug: GV-971
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered PO
Trial: NCT04520412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered PO
Trial: NCT00630565
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
Trial: NCT00768183
Drug: KADIAN Capsule + alcohol (under fasting conditions)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
Trial: NCT00768183
Drug: KADIAN Capsule + alcohol (under fed conditions)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
Trial: NCT03175978
Drug: IGF/MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
Trial: NCT00981305
Drug: Lactate-containing vaginal lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
Trial: NCT00981305
Drug: Placebo vaginal lubricant
RxNorm normalized name: LUBRICANT,VAGINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
Trial: NCT00911547
Drug: Placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo inhaler taken twice daily for 16 weeks
Trial: NCT00911547
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet taken once daily at bedtime for 16 weeks
Trial: NCT03817502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, oral administration, once daily.
Trial: NCT03363997
Drug: Estriol 0.125 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of one vaginal ring
Trial: NCT03363997
Drug: Estriol 0.250 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of one vaginal ring
Trial: NCT03363997
Drug: Estriol 0.500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of one vaginal ring
Trial: NCT00076843
Drug: Hu MiK-Beta-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01590459
Drug: VX-509 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral tablet
Trial: NCT03531931
Drug: Apatinib/Capecitatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
Trial: NCT02432261
Drug: Nestorone® /testosterone gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone® /testosterone combined gel
Trial: NCT02432261
Drug: Testosterone only gel
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone only gel
Trial: NCT03945591
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg IV over 2 hours on Day +3 and +4
Trial: NCT04600141
Drug: Heparin - Therapeutic dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
Trial: NCT04600141
Drug: Heparin - Prophylactic dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
Trial: NCT04209192
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Is the prophylactic drug which will be used in the control group.
Trial: NCT00238550
Drug: Cannabis based medicine extract (CBME)
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01368536
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 15 mg and 25 mg capsule
Trial: NCT01368536
Drug: Placebo of Valturna Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of valturna tablet
Trial: NCT01368536
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
Trial: NCT01621230
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
Trial: NCT01264783
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNS60 for intravenous administration
Trial: NCT04516148
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing per hospital policy
Trial: NCT01264783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline for injection
Trial: NCT03482713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (film-coated tablet) matching gefapixant to be administered orally BID
Trial: NCT05432843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive a treatment with placebo for 8 weeks
Trial: NCT00521456
Drug: ketorolac eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo
Trial: NCT02242266
Drug: Spiriva® HandiHaler® high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium inhalation powder, hard gelatine capsule
Trial: NCT02242266
Drug: Placebo via the blue HandiHaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhalation via the blue HandiHaler®
Trial: NCT02242266
Drug: Placebo via the grey HandiHaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhalation via the grey HandiHaler®
Trial: NCT00210184
Drug: Irinotecan associated to fluorouracil and leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03748108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
Trial: NCT01241461
Drug: LY2584702
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met.
Trial: NCT01489722
Drug: AZD1208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
Trial: NCT00119613
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00302107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Look-a-like placebo tablets under double-blind conditions
Trial: NCT00074269
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01790932
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00293033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02014571
Drug: GSK2878175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
Trial: NCT02014571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
Trial: NCT00453063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sprays in each nostril once daily in the morning
Trial: NCT04052334
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
Trial: NCT01441180
Drug: GS7977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug intervention
Trial: NCT01457144
Drug: RiBVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2
Trial: NCT02352883
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo endocrine therapy
Trial: NCT02637557
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
Trial: NCT01625377
Drug: Mycophenolic Acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of 1440 mg/day from transplantation to month 6 post- transplantation
Trial: NCT01625377
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
Trial: NCT03451266
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
Trial: NCT00808626
Drug: 99mTc-rBitistatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
Trial: NCT02043366
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline is intravenously administrated before anesthesia induction
Trial: NCT04381143
Drug: Aspirin 100 mg Oral Tablet
RxNorm normalized name: aspirin 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg tablet daily
Trial: NCT04381143
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo 1 pill daily
Trial: NCT02043366
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is intravenously administrated
Trial: NCT02043366
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil is intravenously administrated
Trial: NCT02718495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01504620
Drug: insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of insulin
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 capsules (325 mg each), once per day
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 capsules (325 mg each), once per day
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 capsules (325 mg each), once per day
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 capsules (325 mg each), once per day
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 capsules (325 mg each), once per day with supplement
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 capsules (325 mg each), once per day
Trial: NCT00959959
Drug: TOK-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Trial: NCT02833415
Drug: [U-13C3] glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
Trial: NCT02833415
Drug: Placebo (for Empagliflozin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet manufactured to mimic EMPA 10 mg tablet.
Trial: NCT00958256
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
Trial: NCT01769209
Drug: Doxorubicin hydrochloride (HCl)
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
Trial: NCT05999994
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT01769209
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intrathecally (IT) at 15 mg, on Day 15.
Trial: NCT04386057
Drug: LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3214996-daily oral dosage per protocol per 28 day cycle
Trial: NCT00004143
Drug: Campath, Chemo and/or TBI Allo SCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
Trial: NCT00049036
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00049036
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00963183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose.
Trial: NCT02322047
Drug: Placebo (Prazosin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
Trial: NCT02322047
Drug: Placebo (Naltrexone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Dosing Days 1-42: 50mg @ 9PM
Trial: NCT00413400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
Trial: NCT01786655
Drug: NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
Trial: NCT03905408
Drug: 50 mL of 50% Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st dose
Trial: NCT03905408
Drug: 100 mL of 50% Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd dose
Trial: NCT03905408
Drug: 150 mL of 50% Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3rd dose
Trial: NCT03905408
Drug: 200 mL of 50% Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4th dose
Trial: NCT04450446
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy
Trial: NCT02006888
Drug: IBI-10090
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02006888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00371826
Drug: Cyclosporine (Calcineurin Inhibitor (CNI))
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00725374
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
Trial: NCT02616692
Drug: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
Trial: NCT02104752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive, matched placebo (Sugar Pill)
Trial: NCT01769378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT04356209
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
Trial: NCT00144690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04676178
Drug: PRA023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRA023
Trial: NCT03665454
Drug: Standard of Care Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
Trial: NCT00168701
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02505295
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion like intervention group
Trial: NCT00436241
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 po bid on days 1-10 of each 2 week cycle
Trial: NCT01358851
Drug: LAS41005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03624985
Drug: Placebo Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
Trial: NCT03532841
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet of the same shape,color and taste will be given in the placebo arm
Trial: NCT01842100
Drug: Universal antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice daily for 7 days starting on the day of induced abortion
Trial: NCT01667484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no